Clinical trial · Observational
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Soft Tissue Sarcomas
NCT06644287CI-TRIAL-00083713recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for advanced soft tissue sarcomas.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Soft Tissue Sarcomas | Soft Tissue Sarcoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Diagnosis of advanced soft tissue sarcomas
- description
- Patients diagnosis of advanced soft tissue sarcomas require immunotherapy or combination immunotherapy after evaluation
Primary outcomes (3)
- measure
- Evaluation the responses to immunotherapy of advanced soft tissue sarcomas
- timeFrame
- up to about 10 weeks
- description
- The value of 68Ga-grazytracer PET in monitoring responses to immunotherapy of advanced soft tissue sarcomas
- measure
- Standardized uptake value(SUV)
- timeFrame
- up to about 10 weeks
- description
- SUV of 68Ga-grazytracer uptake on PET/CT images for tumor lesions
- measure
- Target-to-background ratio(TBR)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Pathological and clinical diagnosis of advanced soft tissue sarcomas, pathological types include: fibrosarcoma, liposarcoma, undifferentiated pleomorphic sarcoma, epithelioid sarcoma, rhabdomyosarcoma, synovial sarcoma, alveolar soft-part sarcoma, leiomyosarcoma, clear cell sarcoma, malignant schwannoma, angiosarcoma. 2. Consider immunotherapy or combined immunotherapy based on clinical judgement. 3. Signed and dated informed consent form. 4. Commitment to comply with research procedures and co-operation in the implementation of the full research process. 5. Aged 6-80 years old. Exclusion Criteria: 1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc. 2. Intestinal perforation, complete intestinal obstruction 3. Pregnant women and women who may be pregnant, women who are breastfeeding. 4. Non-compliant person
References
Publications (0)
Data not yet available
No reference posted for this study.